Abstract Number: 170 • 2012 ACR/ARHP Annual Meeting
Relative Risk of Infusion Reactions with KRYSTEXXA® (pegloticase) From Post-Approval Safety Data: Results From Sept 2010 to June 2012
Background/Purpose: During randomized clinical trials (RCTs) with pegloticase, the incidence of infusion-related reactions (IRs) was 26% including 5 cases of anaphylaxis (determined post-hoc using published…Abstract Number: 159 • 2012 ACR/ARHP Annual Meeting
Clinical Efficacy Outcomes with up to 3 Years of Pegloticase Treatment for Refractory Chronic Gout
Background/Purpose: Pegloticase, a recombinant modified mammalian uricase conjugated to mPEG, was approved for use in refractory chronic gout in the US in 2010. The Phase…Abstract Number: 160 • 2012 ACR/ARHP Annual Meeting
Pegloticase Long-Term Safety: Data From the Open-Label Extension Trial
Background/Purpose: Pegloticase is a recombinant modified mammalian uricase conjugated to mPEG and approved for treatment of refractory chronic gout. Pegloticase safety was evaluated during 2…Abstract Number: 140 • 2012 ACR/ARHP Annual Meeting
Patients That Continue to Flare Despite Apparent Optimal Urate Lowering Therapy
Background/Purpose: Gout is a common inflammatory arthritis and its worldwide prevalence is increasing. The purpose of this study is to describe physician, patient and treatment…
- « Previous Page
- 1
- …
- 5
- 6
- 7